Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04641351 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Corticosteroid Meniscectomy Randomized Trial

Study acronym: CoMeT
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Study completion pushed from Aug 1, 2026 to Aug 1, 2027v12
  2. Notable Primary completion date: Jan 30, 2026 to Aug 1, 2026
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
    v11
  3. Minor Primary completion date: Sep 30, 2025 to Jan 30, 2026v10
  4. Minor Primary completion date: Jun 30, 2025 to Sep 30, 2025
    • Study completion date: Aug 1, 2025 to Aug 1, 2026
    v9
  5. Minor Primary completion date: Mar 22, 2025 to Jun 30, 2025
    • Study completion date: May 1, 2025 to Aug 1, 2025
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Notable Primary completion date: Mar 22, 2024 to Mar 22, 2025
    • Study sites: 1 to 2
    v7
  2. Minor 2 versions Re-verified since Jun 30, 2022, no change to tracked fieldsv5-v6
  3. Minor Trial status: Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Mar 29, 2021 to May 27, 2021
    • Site details revised
    v4
  4. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Start date: Feb 22, 2021 to Mar 29, 2021
    • Primary completion date: Feb 22, 2024 to Mar 22, 2024
    • Study completion date: Apr 1, 2025 to May 1, 2025
    • Site details revised
  5. Notable Start date: Dec 1, 2020 to Feb 22, 2021
    • Primary completion date: Dec 1, 2023 to Feb 22, 2024
    • Study completion date: Dec 1, 2024 to Apr 1, 2025
    v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Synovitis has an important role in the symptoms and progression of Osteoarthritis (OA). Inflamed synovium has been associated with both increased symptoms and increased progression in OA patients. Furthermore, synovitis observed during knee arthroscopy in our patients undergoing arthroscopic partial meniscectomy (APM) was associated with worse symptoms while adjusting for confounding factors.Therefore, a better understanding of synovitis as a predictor of outcome after APM and as a target for treatment is needed to improve outcomes in this patient population. Triamcinolone has been shown to decrease synovitis-associated outcomes in both animal and human studies after anterior cruciate ligament (ACL) injury. In a porcine model of ACL injury, treatment with triamcinolone resulted in decreased formation of synovitis-related collagen breakdown products as well as decreased cellularity of the synovium.And in a trial of triamcinolone injected after ACL injury, similar findings of decreased C-telopeptide of type II collagen (CTX-II), associated with collagen type II breakdown, was found in knees administered triamcinolone compared to placebo controls.
Trial Details
NCT Number NCT04641351
Lead Sponsor The Cleveland Clinic
Collaborators: Arthritis Foundation
Conditions
(from sponsor)
Osteoarthritis, Knee, Meniscus Tear, Meniscus; Degeneration, Synovitis
Related terms Osteoarthritis, Knee, Synovitis
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov